Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
Carla TortorellaAlessandra AielloClaudio GasperiniChiara AgratiConcetta CastillettiSerena RuggieriSilvia MeschiGiulia MatusaliFrancesca ColavitaChiara FarroniGilda CuzziEleonora CiminiEleonora TartagliaValentina VaniniLuca ProsperiniShalom HaggiagSimona GalganiMaria Esmeralda QuartuccioAndrea SalmiFederica RepeleAnna Maria Gerarda AlteraFlavia CristofanelliAlessandra D'AbramoNazario BevilacquaAngela CorpolongoVincenzo PuroFrancesco VaiaMaria Rosaria CapobianchiGiuseppe IppolitoEmanuele NicastriDelia Golettinull nullPublished in: Neurology (2021)
This study provides Class III data that COVID mRNA vaccination induces both humoral and cell-mediated specific immune responses against viral spike proteins in a majority of MS patients.
Keyphrases
- immune response
- sars cov
- end stage renal disease
- mass spectrometry
- multiple sclerosis
- ms ms
- dendritic cells
- respiratory syndrome coronavirus
- newly diagnosed
- ejection fraction
- coronavirus disease
- toll like receptor
- chronic kidney disease
- prognostic factors
- single cell
- peritoneal dialysis
- binding protein
- electronic health record
- patient reported outcomes
- big data
- inflammatory response
- mesenchymal stem cells
- machine learning